“We want to work with great partners with complementary skills and resources."
- Sylvie Ryckebusch, Chief Business Officer at BioInvent.
Successfull collaborations build the future
BioInvent is a collaborative company with a long history of fruitful academic and industry partnerships. We are open to collaborating with science-driven organizations with complementary resources and expertise. Our strategic collaborations span research, development, product licenses, as well as commercial partnerships.
Business development supports the organization with crafting partnering strategies, building competitive intelligence frameworks, nurturing long-term relationships, implementing transactions of varying degrees of complexity, and managing existing alliances.
BioInvent aims to establish development and commercial partnerships for our clinical assets with world-class pharmaceutical companies. While success in the clinic is usually a prerequisite for establishing such partnerships, our world-class science and expertise in identifying and developing first-in-class cancer therapeutics sets BioInvent apart from many of our peers. Our recognized world-class expertise has also attracted research partnerships with global pharmaceutical companies, as well as supply agreements to access successful commercial drugs for our combination trials. Each of our partnerships is a unique opportunity to showcase our technologies and programs and enable our scientists to interact with high quality research and development groups worldwide.
We also seek to explore how our antibodies can be combined with innovative technologies to further enhance their potential and create truly unique products.
Active partnerships:
 |
|
 |
|
  |
|
 |
|
 |
|
FOUR CLINICAL PROJECTS OUTLICENSED
BioInvent currently has four clinical projects outlicensed to other companies. Long-term, these projects hold real financial potential. In the short term, say five years, BioInvent may receive minor clinical milestone payments, but the upside in these projects lies in commercial milestones and potential royalties five to ten years from now. It is impossible to know if any of BioInvent’s external projects will go all the way to market but statistically it is highly probable that at least one or two will be successful.
